dianthustx.com - DNTH Total Company Value-to-Revenue Ratio

Official company branding of dianthustx.com (DNTH)

Dianthus Therapeutics (DNTH) is implementing eco-friendly laboratory standards and strict reagent disposal controls. The EV/Sales trend visualizes the enterprise value of the business relative to revenue, where the current figure stands at 1448691.18. The company is developing a system of targeted complement inhibitors to combat autoimmune pathologies, and its investment attractiveness relies on the scientific authority of the team and initial successes.

DNTH dianthustx.com Enterprise Value-to-Revenue Ratio (11/23/2025 - 11/20/2026)

Dianthus Pharma - analytical breakdowns and key metrics (DNTH)

- share price and consensus valuation forecast:
Fundamental valuation:DNTH - dianthustx.com
Manufactured products of Dianthus Therapeutics Inc

Capital seeks to differentiate stable assets from speculative instruments. Antibody patents and stringent FDA oversight provide Dianthus Therapeutics (DNTH) with high market defensibility. By analyzing the company's EV/Sales ratio, an investor assesses the total enterprise value relative to revenue, excluding debt load. The stability of this curve allows for the distinction between fundamental maturity and market inertia. This confirms the long-term sustainability of the valuation amidst capital-intensive R&D expenditures.

Competitor analysis

ARGX - EV/Sales Multiple|BNTX: EV/Sales Multiple|ABVX (Abivax SA) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio ADMA Corp|Enterprise Value-to-Revenue Multiple Protagonist Therapeutics PTGX|Company Value to Revenue IMVT (Immunovant Therapeutics)|Total Company Value-to-Revenue Ratio kiniksa.com|Enterprise Value-to-Revenue Ratio Grifols Biemat GRFS|Enterprise Value-to-Revenue Coefficient ADPT (Adaptive Biotechnologies Corporation)|celldex.com - EV/Sales Multiple|Total Company Value-to-Revenue Ratio Aurinia Pharma AUPH|biocryst.com (BCRX) - Enterprise Value-to-Revenue Ratio|Vera Therapeutics, Inc. - Business Value to Revenue|PHVS (Pharvaris NV) - EV/Sales Multiple|ABCL: Business Value to Revenue|Enterprise Value-to-Revenue Ratio Tourmaline Bio, Inc. (TRML)|PGEN (Intrexon) - Business Value to Revenue|EV/Sales Multiple PHAR (Pharming Corp)|nektar.com (NKTR) - Enterprise Value-to-Revenue Multiple|UPB - Enterprise Value-to-Revenue Ratio|Business Value to Revenue ZBIO (Zenas Biopharma)|IMNM: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Gossamer Bio, Inc. (GOSS)|Enterprise Value-to-Revenue Ratio KalVista Pharmaceuticals|Septerna Inc (SEPN) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple PVLA|SVRA (Savara) - Business Value to Revenue|Rigel Pharma - Company Value to Revenue|Total Company Value-to-Revenue Ratio AnaptysBio Corp (ANAB)|ATXS: Company Value to Revenue|Business Value to Revenue ENGN (enGene Holdings Inc.)|RAPT Therapeutics Inc. (RAPT) - Enterprise Value-to-Revenue Ratio|Aerovate Therapeutics Inc (JBIO) - EV/Sales Multiple|ACRS (Aclaris Therapeutics, Inc) - EV/Sales Multiple|Kyverna (KYTX) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple TLSA|Company Value to Revenue Cabaletta Bio, Inc. CABA|Ventyx Biosciences - Company Value to Revenue|THTX: Company Value to Revenue Ratio|AVTX - Enterprise Value-to-Revenue Ratio|ELDN: Enterprise Value-to-Revenue Ratio|Agenus Inc. (AGEN) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Climb Bio Inc|ZURA (Zura Bio Ltd) - EV/Sales Multiple|EV/Sales Multiple aTyr Pharma Inc|EV/Sales Multiple ADAG|Total Company Value-to-Revenue Ratio ImageneBio|EV/Sales Multiple STTK (Shattuck Labs Inc)|EV/Sales Multiple Equillium, Inc. EQ|CNTB - Enterprise Value-to-Revenue Ratio|Immunic Therapeutics (IMUX) - Company Value to Revenue|ATRA: EV/Sales Multiple|InflaRx GmbH (IFRX) - EV/Sales Multiple|XFOR (x4pharma.com) - EV/Sales Multiple|EV/Sales Multiple Adicet Bio|Enterprise Value-to-Revenue Ratio Celularity Inc (CELU)|Company Value to Revenue INmune Bio Corp INMB|Enterprise Value-to-Revenue Ratio Barinthus Biotherapeutics plc BRNS|KZR - Company Value to Revenue|sabbiotherapeutics.com - EV/Sales Multiple|akaritx.com (AKTX) - Company Value to Revenue|ENLV: EV/Sales Multiple|QTTB (Q32 Bio Inc) - Enterprise Value-to-Revenue Ratio|GOVX (geovax.com) - EV/Sales Multiple|EV/Sales Multiple Edesa Biotech Corp|EV/Sales Multiple IBIO|Company Value to Revenue Carisma Tx CARM|Enterprise Value-to-Revenue Ratio XTL Biopharmaceuticals Ltd XTLB|EV/Sales Multiple Bolt Biotherapeutics BOLT|HCW Biologics - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple aptevotherapeutics.com|AIM (AIM ImmunoTech, Inc.) - Company Value to Revenue|Aditxt Corp - Business Value to Revenue|GRI (GRI Bio Inc) - EV/Sales Multiple|EV/Sales Multiple XORTX Therapeutics Inc|Enterprise Value-to-Revenue Ratio Vyome Therapeutics (HIND)|REVB - Enterprise Value-to-Revenue Multiple|Enterprise Value-to-Revenue Ratio Indaptus Therapeutics, Inc. INDP|EV/Sales Multiple scinai.com SCNI|CalciMedica Inc - EV/Sales Multiple|AFMD - EV/Sales Multiple|ALLK: EV/Sales Multiple|Enterprise Value to Sales Volume HOOK (HOOKIPA Pharma, Inc.)|IGMS (IGM Biosciences) - EV/Sales Multiple|ITOS: Business Value to Revenue|Company Value to Revenue OCEA (Ocean Biomedical)|TCBP: Enterprise Value to Sales Volume|Enterprise Value-to-Revenue Ratio Third Harmonic Bio Inc THRD